QGA
STLNW

Q Global Advisors’s Starling Oncology, Inc. Warrant STLNW Stock Holding History

Q Global Advisors’s Portfolio STLNW Stock Details STLNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-97,300
Closed -$168K – 164
2021
Q2 		$168K Buy
+97,300
New +$131K 0.12% 83

Other funds holding STLNW

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
USPCM
Union Square Park Capital Management New York $176M AUM 51.52% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Q Global Advisors's STLNW Position: Q3 2021 in Review

Q Global Advisors sold out of Starling Oncology, Inc. Warrant (STLNW) in Q3 2021, closing a stake of 97,300 shares — an estimated $168K sold.

Q Global Advisors first reported a position in STLNW in Q2 2021 and held it in 1 quarter. The position peaked at $168K in Q2 2021. 21 funds tracked by Wall St. Rank hold STLNW as of Q3 2021.

  • Q Global Advisors reported no remaining Starling Oncology, Inc. Warrant position as of Q3 2021 after selling out during the quarter.
  • Q Global Advisors sold 97,300 Starling Oncology, Inc. Warrant shares in Q3 2021, an estimated $168K.
  • Q Global Advisors first reported a position in Starling Oncology, Inc. Warrant in Q2 2021 and held it in 1 quarter.
  • Q Global Advisors's Starling Oncology, Inc. Warrant position peaked at $168K in Q2 2021.
  • 21 funds tracked by Wall St. Rank held Starling Oncology, Inc. Warrant as of Q3 2021.

Based on Q Global Advisors's 13F filing for Q3 2021, filed 16 Nov 2021.